| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a7ebd2ce5ef7e691bd44c48a88a2bfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8381805eba6d034fc77bd230dd02e6e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8073450a491d200d05b09b9beb6f0ec6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2020-03-12^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1807e6289fe01877a744cb695306af58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a668e771333a2815f76dd009c2f3b25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfea4ed72eb3b048207e738aafc6c124
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40d2961e975a5ef3190375bc7e1d5dc9 |
| publicationDate |
2020-09-17^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020186101-A1 |
| titleOfInvention |
Detection means, compositions and methods for modulating synovial sarcoma cells |
| abstract |
The present invention provides novel compositions and methods based on the discovery of the mechanisms and gene expression programs associated with synovial sarcoma. In particular, core oncogenic programs were expressed by a distinct subpopulation of malignant cells and associated with poor clinical outcome, a cell cycle program distinguished cycling from non-cycling cells, with cycling cells having a tendency to be poorly differentiated and indicative of increased risk of metastatic disease, and a (de)differentiation program that can identify poorly differentiated cells, the absence of which was prognostic of metastasis free survival. Methods of treatment include use of HDAC and CDK4/6 inhibitors to block oncogenic program to selectively target synovial sarcoma cells. Finally, macrophages and T cells can mimic the effect of SS18-SSX inhibition by secreting TNFa and IFNg, which allows for adoptive cell therapy to provide cells with increased expression of TNFa and IFNg. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114512183-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114512183-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022098765-A1 |
| priorityDate |
2019-03-12^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |